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Abstract
Background: In Central Asia, there is a need to update information about the situation of people who use (opioid)
drugs (PWUD), especially regarding their access to and utilization of health care services. The aim of the study was
to gather information about two different groups of drug users in Kazakhstan and Kyrgyzstan.
Methods: In 2013, two groups of PWUD were recruited in Kazakhstan and in Kyrgyzstan in order to gather quantitative
data via interviewer-administered questionnaires. PWUD registered with the Narcological Register were allocated to
group A while non-registered PWUD were allocated to group B. Interviews were conducted in the office of the
Narcological Register as well as in low-threshold facilities. Participants reported about their drug use patterns, health
status, and utilization of health services as well as barriers to utilization.
Results: The sample consisted of N = 600 PWUD (301 registered and 299 non-registered PWUD) from Kazakhstan and
N = 900 PWUD (450 registered and 450 non-registered PWUD) from Kyrgyzstan. Both groups—registered (group A) and
non-registered (group B)—consisted of mainly male long-term intravenous opioid users. We found high rates of current
(last 30 days) opioid use (group A up to 70 %; group B up to 84 %). Most PWUD were burdened with poor physical and
mental health. The prevalence of infectious diseases added up to 19 % (group A) or 13 % (group B) regarding HIV, 56 %
(group A) or 30 % (group B) regarding HCV, and 24 % (group A) or 20 % (group B) regarding tuberculosis. Registered and
non-registered PWUD reported high rates (95 or 82 %) of lifetime use of health services for PWUD. Drug-related services
were utilized less often, especially among the non-registered PWUD (13 %). The most important barriers preventing
PWUD from accessing services were the belief not to need treatment, doubts about the effectiveness of treatment,
mistrust of treatment regime/staff, and fear of being registered with the Narcological Register (mainly group B).
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Conclusions: Results show that access to the health care system for non-registered PWUD is realized mainly through
low-threshold facilities. Opioid substitution treatment, which is an important pillar in the treatment of PWUD, is normally
only available for those registered with the Narcological Register. Instead, access to opioid substitution treatment
(especially in Kazakhstan) should be expanded and granted without prior registration, as this poses an important barrier
for PWUD’s utilization of drug treatment services. Further, there seems to be a need for the provision of specific and
target group-related information about drug treatment services in order to reduce existing reservations among PWUD as
to the necessity and effectiveness of modern drug treatment.
Keywords: PWUD, Central Asia, Kazakhstan, Kyrgyzstan, Opioid drug use, Access to health care, Harm reduction, Barriers
to service utilization, HIV, HCV
Background
Kazakhstan and Kyrgyzstan are two post-Soviet republics
located in Central Asia. Kazakhstan’s territory adds up
to 2,724,900 km2. Even though the country is larger than
Western Europe, only approximately 17.5 million people
(of mostly Kazakh and Russian ethnicity) live in Kazakhstan
[1]. The World Bank classified Kazakhstan as an “upper-
middle-income country with per capita GDP of nearly
US$13,000 in 2013.” [2].
Kyrgyzstan, extending to 198,500 km2, has a population
of 5.5 million people [3]. The biggest ethnicities are Kyrgyz,
Uzbek, and Russian. In comparison with Kazakhstan,
Kyrgyzstan is a much poorer country (per capita GDP
US$1300) [4].
The development of the health care system in general
and of specific drug treatment programs in particular is
of well-known significance to reducing the public
health-related consequences of substance use, especially
the incidence of HIV among people who use drugs
(PWUD)1 [5]. This interrelation is of particular relevance
to young post-Soviet countries in Central Asia such as
Kazakhstan and Kyrgyzstan for two reasons: Firstly, the
World Drug Report 2015 [6] has indicated one of the
highest annual prevalence rates for the opioid use in the
world for this region (0.9 %). Secondly, HIV prevalence
among PWUD in Central Asia is high and still rising [7–9]
(see below).
In the past few years, many international and Central
Asian stakeholders have repeatedly pointed out the need
to update the drug use-related data for the region of
Central Asia: “At present it is extremely difficult to ob-
tain an objective picture of drug consumption both
among the general population and among specific
groups […] because of the lack of a good-quality epi-
demiological study in the country.” [10]. Though there
are miscellaneous reports related to drug use, drug traf-
ficking, and drug seizures [11, 12], “reliable data on drug
use and its patterns in the general population of the
countries of Central Asia are not available” [13]. Some
information about the drug situation in Central Asia is
only based on experts’ opinions; the last survey on the
drug situation in Kazakhstan was conducted in 2001 and
suffers from methodological deficits (regarding sampling,
questionnaire, etc.) which make it difficult to generalize
its results [10, 13]. This study reported that 1.7 % of the
general population used drugs. Among these, 31.6 %
were dependent on opioids and 81.3 % on cannabis [14].
The estimate of problem drug use (injecting drug use) in
the previous 12 months among the general Kazakh
population in 2012 was 1 % [15].
Regarding Kyrgyzstan, drug use among the general
population was examined in an estimation study in
2002, but detailed information on the methodology of
the study is lacking. The authors reported 2.6 to 3.3 % of
the population (16 to 64 years old) as drug users and
1.8 % of the population as problem drug users [16].
For some countries—Kazakhstan and Kyrgyzstan,
for example—government statistics can be found:
“Narcological centers” (NCs), which are located in all
provinces, are in charge of PWUD and their treatment.
PWUD who access the public drug treatment system or
come to the attention of the police for an offense have to
undergo a urine test for illegal drugs. If the result of the
test is positive, they will be registered. On first contact to
the NC, a person is registered either in the “dispensary
narcological register” (if diagnosed according to ICD-10)
or in the “prophylactic narcological register” (if no addic-
tion was diagnosed). NCs collect sociodemographic data
as well as drug use data (incl. possible diagnoses) and the
results of somatic and toxicological medical examinations
of PWUD in a database called the “Narcological Register.”
As law enforcement agencies have access to personal data
in the register, the Narcological Register is also used, e.g.,
to prevent PWUD from driving, possessing a weapon, or
to ban them from different fields of employment, such as
the military, the police, or the educational system. Once
registered, the PWUD has to appear in person at the NC
for a quarterly examination by a narcologist (specialized
medical doctor). In order to be removed from the Kazakh
“dispensary register,” the PWUD have to show abstinence
from illegal drugs and alcohol for at least 5 years; in
Kyrgyzstan, this is the case after 3 years. PWUD who are
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in the “prophylactic register” will be removed if they prove
to be abstinent for 3 years (in Kazakhstan) or 1 year (in
Kyrgyzstan). Further reasons for deletion from the register
are a move to a region outside the territory covered by the
NC, imprisonment, or death [10, 17]. In 2011, 30,259
PWUD were registered with narcology in Kazakhstan
[10]. Regarding Kyrgyzstan, the only data available are
from 2008: 9057 PWUD were registered with narcology in
this country [18].
Drug treatment in Kazakhstan is free of charge (except
for drug treatment offered by the very confined private
narcological sector) [10]; in Kyrgyzstan, the expenses are
covered by the patients or the medical insurance [18]. In
2013, a group of treatment experts were asked to assess
the availability of key treatment offers in different Cen-
tral Asian countries: They reported detoxification to be
fully available in Kazakhstan as well as in Kyrgyzstan,
whereas the availability of inpatient drug-free medical
treatment was described as moderate in both countries.
Outpatient drug-free medical treatment was fully avail-
able in Kazakhstan; in Kyrgyzstan, only moderately.
Availability of opioid substitution treatment (OST) was
assessed as rare regarding Kazakhstan and as moderate
regarding Kyrgyzstan. Psychological support and therapy
was available moderately in both countries, whereas so-
cial rehabilitation was available only rarely in Kazakhstan
and Kyrgyzstan [13].
In 2011, 2972 PWUD underwent treatment in
Kazakhstan, and 3277 PWUD in Kyrgyzstan [10, 13]. Treat-
ment rates (PWUD treated per estimated number of all
PWUD) are significantly higher in Kyrgyzstan (17.3 %) than
in Kazakhstan (2.5 %). In 2011, OST was provided by three
units in Kazakhstan, serving 115 PWUD (detoxification, 33
units; 1579 patients). In Kyrgyzstan, 20 units provided OST
in 2011, covering 1428 PWUD (detoxification, 50 units; the
exact number of patients undergoing detoxification was in-
determinate) [10, 13, 16]. Eligibility criteria for OST in the
region are not clearly defined. Among others, the main cri-
terion is a history of unsuccessful narcological treatment at-
tempts. Occasionally, there are special “commissions”
(sometimes they include members without any medical
background) that decide about each single PWUD’s access
to OST [19]. The number of injecting drug users who had
contact to harm reduction programs in 2011 in Kazakhstan
was 79,579; in Kyrgyzstan, the respective number is only
available for 2010 and amounts to 9120 persons [13].
Data from the Narcological Register only reflect a small
part of the actual situation as they only cover approxi-
mately one third (44,825 persons) of the estimated inject-
ing PWUD (123,640 persons) in Kazakhstan [10]. A lack
of information exists especially concerning the situation
and the utilization of services of PWUD who are not regis-
tered with the NCs. Another data source is the Sentinel
Epidemiological Surveillance which is conducted under
the supervision of the “Republican AIDS Centre” [15].
These investigations are mainly concerned with gaining
epidemiological information in Kazakhstan and therefore
only partly cover the health service situation regarding
PWUD. Additionally, the quality of these data and infor-
mation is weak due to methodological problems. The
methodology of the sampling procedure as well as the cal-
culation of the sample size is assessed as incorrect; inter-
viewing techniques, questionnaire design, and data
analysis, e.g., generalization of the results on a national
level, are considered as questionable [10].
As illustrated, there is a need for updated data on the
(health service) situation of PWUD in Central Asia. Fur-
thermore, the incidence of HIV among PWUD is high
(KAZ 2011, 3.8 %; KRG 2010, 14.6 %) [10, 16] and—in
most of the region’s countries—continues to increase [7, 8]
in spite of many efforts by national governments, NGOs,
and international development aid organizations. The pro-
portion of PWUD infected with HCV among all PWUD is
reported as 61.3 % for Kazakhstan (2011) and as 50.4 % for
Kyrgyzstan (2010) [10, 16]. These facts led the UNODC
Regional Office for Central Asia to initiate a comprehen-
sive study titled: “Assessment of adequacy of health ser-
vices for people who use drugs (PWUD) in countries of
Central Asia and in the Republic of Azerbaijan.” The study
protocol along with the study instruments (questionnaires,
templates, guides, and forms) was developed by members
of the Centre for Interdisciplinary Addiction Research of
the University of Hamburg (CIAR) in close cooperation
with the UNODC project staff. Selected results from this
study are presented in this article.
The study aimed not only to facilitate a better under-
standing of the drug-using population but also to allow for
an appraisal of the accessibility of health care and drug
treatment services which should be provided to PWUD ac-
cording to WHO criteria, i.e., among others, geographical
accessibility, availability of low-threshold services, compre-
hensive assessment and treatment plans, evidence-based
pharmacological and psychosocial interventions, and med-
ically supervised withdrawal [5, 20–22]. In this article, we
focus in detail on the following main objectives: (1) to de-
scribe the opioid-using population regarding their sociode-
mographic characteristics, their health status, and their
patterns of drug use; (2) to investigate their utilization of
health care services and drug treatment services; and (3) to
describe the barriers that restrain PWUD from utilizing
drug treatment services. Based on these results, we develop
recommendations for improving the effectiveness and effi-
ciency of health and social protection services for PWUD
in Kazakhstan and Kyrgyzstan.
Methods
In order to achieve the objectives of the study, a mixed
methods approach including quantitative and qualitative
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components was used. In this article, we present results
from one of the sub-studies, namely the quantitative sur-
vey of registered and non-registered PWUD.
Sampling procedure, recruitment, and inclusion criteria
In order to reach the “hidden population” not in contact
with the health care or drug treatment system, we de-
cided to stratify our sample in order to examine two
groups of PWUD: Group A consists of PWUD who are
registered with a NC (i.e., they are currently in contact
with the public health care or drug treatment system),
and group B consists of PWUD not registered with nar-
cology (i.e., they are not in contact with the public
health care or drug treatment system).
Group A was generated via the following sampling
procedure: The local UNODC research teams selected
the recruitment sites. Registered PWUD were recruited
consecutively as they appeared at their NC. The sam-
pling frame for the registered drug-using population is
the Narcological Register.
In the case of the non-registered PWUD, non-
probability sampling methods appeared to be more suit-
able [23, 24]. For this study, an approach similar to
snowball sampling was used. In this approach, “seeds”
were set by researchers, and every seed was supposed to
recruit up to three members of the non-registered
PWUD (first wave). These recruited people were sup-
posed to recruit up to three further participants (second
wave). After the second wave, the recruitment process
was stopped in order to avoid recruitment of PWUD
who all belong to only one (or very few) social net-
work(s). This would have borne the risk not to attain
enough variance regarding the desired data and informa-
tion needed to answer our research questions.
The required sample size of 300 PWUD per province
(150 for each group) was determined with “EpiInfo,” a
software application for calculating sample sizes provided
by the Centers for Disease Control and Prevention [25].
In Kazakhstan, the local research teams recruited
PWUD in four cities of the province East Kazakhstan
oblast and in four cities of the province Karaganda ob-
last. In Kyrgyzstan, recruitment took place in three prov-
inces: Bishkek city, Osh oblast (four cities), and Chuy
oblast (three cities, four villages).
The sampling procedure in Kazakhstan started at the
end of March 2013 and lasted until end of May 2013. In
Kyrgyzstan, the first interviews were conducted by end
of August 2013 and the last at the beginning of Novem-
ber 2013. The recruitment of PWUD for group A took
place in the office of the local NC. At the starting point
of the recruitment period, all registered PWUD who vis-
ited the NC were informed about the study, were asked
for permission for a screening, and were screened con-
secutively. If a person met the inclusion criteria, the
interviewee was informed about the voluntariness and
anonymity of the participation and, if willing to partici-
pate, was then asked to sign the informed consent form
and the interview was conducted.
Inclusion criteria are as follows:
 Currently registered with narcology and opioids as
main drug, i.e., opioid use as reason for registration
at NC → allocation to group A
 Currently not registered with narcology (self-reported)
and current opioid use, i.e., at least once in the last
30 days (self-reported)→ allocation to group B
 Not yet interviewed in this study
 Age 16 years or older
 Understanding of Russian or local language
 Cognitively able to follow the interview
 Not psychotic
 Willing to participate and having signed the
informed consent sheet
The interviews took place partly in a separate room in
the NC and partly in a scheduled appointment outside
the NC, e.g., at trust points (low-threshold services that
provide safe injecting equipment, information on safe
drug use or safe sexual behavior, etc. [26]). The inter-
viewers were given prior training by UNODC staff who
provided instruction regarding filtering processes (i.e.,
questions about health services in prison should only be
asked to interviewees with prison experience).
The members of group A were asked after their inter-
view if they knew any non-registered PWUD. If they did
so and if they were willing to recruit them for the study,
they were given three contact cards which they were to
hand out to a PWUD in their circle of acquaintances
whom they regarded as potentially eligible for group B.
The conduction of interviews with the members of
group B was realized in other locations: some were
interviewed in rooms of NGOs, some in AIDS centers
or trust points, and some in rental apartments.
Screening and recruitment were conducted until the
intended sample size of each group was reached. An in-
centive in the form of a pre-paid mobile phone card was
given to all interviewees after the successfully conducted
interview.
Figure 1 gives an overview of the sampling processes
in Kazakhstan and in Kyrgyzstan.
Data collection and processing
The data for the quantitative cross-sectional survey was
collected by using a structured paper-based questionnaire
containing approximately 100 questions. The question-
naire consisted of questions about the sociodemographic
background of PWUD, their drug use patterns including
risk behavior, questions about their physical and mental
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health status, PWUD’s accessibility and utilization of
health services, and barriers to utilization of drug-related
services. Some well-established measurement instruments
were integrated into the questionnaire: the health assess-
ment section from the Maudsley addiction profile [27]
and questions from the treatment demand key indicator
[28]. The time to conduct each interview averaged at
about 50 min.
The UNODC data team entered the data and provided
an Excel data set. Data were imported into SPSS software,
and after running plausibility checks, data were analyzed
using SPSS software for Windows, version 22. Differences
between groups A and B were analyzed for significance
using chi square tests and t tests, respectively.
Results
Sample characteristics
There were 600 participants recruited from Kazakhstan
and 900 from Kyrgyzstan (see Table 1 for detailed sam-
ple characteristics). Participants in both groups, in both
countries, were predominantly male. On average, regis-
tered PWUD were older than non-registered PWUD.
Around two thirds of the interviewees specified their na-
tionality as Russian. The only exception was group A
from Kyrgyzstan where the proportion of Russians was
merely half as big.
The social situation of most of the interviewees ap-
peared to be relatively positive as the majority indicated
their accommodation situation as stable; more than half
of PWUD lived in a stable partnership (partnership sta-
bility was based on the judgment of the respondent).
Further, around 60 % of both groups in Kazakhstan and
up to 80 % in Kyrgyzstan lived together with minors
(under 18 years old).
Most of the interviewees had completed at least sec-
ondary school education. This rather high level of educa-
tion was also reflected in the employment rates: Most of
the PWUD in this study were either regularly or occa-
sionally employed.
In Kazakhstan, registered and non-registered PWUD
only differed significantly in age; in Kyrgyzstan, this ap-
plied also to stable housing and occasional employment.
Drug use behavior
In both countries, the mean age of onset for regular use of
opioids was lower for non-registered PWUD compared to
registered PWUD. This also applied to the age of first
injecting drug use in Kyrgyzstan, but in Kazakhstan, there
was no significant difference.
Intravenous drug use in the last 30 days was docu-
mented for almost all PWUD in both countries, and her-
oin was the dominant drug.
Regarding the 12-month prevalence of opioids, cannabis,
and alcohol, the registered and non-registered PWUD in
Kazakhstan did not differ significantly except for alcohol
use. In Kyrgyzstan, however, the PWUD from group B had
an explicitly higher drug consumption prevalence rate—-
except for opium—than the PWUD from group A. The
same pattern was found in both countries regarding the
30-day prevalence.
Health status
In both countries, non-registered PWUD had a better
physical and mental health status than registered PWUD
(see Table 1; lower scores correspond to better health sta-
tus). The score values were comparable to those mentioned
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Fig. 1 Scheme of sampling process
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Table 1 Sample characteristics: sociodemographics, drug use behavior, health status, and overdose experience
Kazakhstan Kyrgyzstan








N = 301 N = 299 N = 450 N = 450
Male 76.4 75.3 87.8 71.6*
Age (years): mean (SD) 34.1 (7.8) 32.1 (8.3)* 39.5 (7.7) 36.3 (9.0)*
Nationality
Russian 64.1 62.5 28.7 47.1*
Kazakh 22.9 21.1 0.7 0.9
Kyrgyz 1.0 2.0 18.2 18.0
Uzbek 0.7 1.0 24.4 16.4*
Others 17.2 14.7 28.0 19.4*
Stable housinga 86.2 86.9 89.9 74.9*
Stable partnershipb 53.2 56.6 65.4 62.3
Living together with minor child/childrenc 58.0 60.5 72.5 80.7
Education: secondary school completed or higher 89.0 90.6 81.9 78.4
Employment situation
Regularly employedd 52.1 54.8 37.2 38.5
Occasionally employed 29.1 28.6 39.1 53.5*
Drug use behavior
Age at onset of regular use of heroin (years): mean (SD) 24.1 (7.0) 22.4* (7.9) 27.2 (7.6) 24.3* (5.7)
Age at onset of i.v. use (years): mean (SD) 20.7 (4.7) 21.0 (5.2) 25.2 (7.8) 22.8* (5.6)
i.v. use in the last 30 dayse 99.0 97.1 98.6 92.8
12-month prevalence
Heroin 93.2 94.5 50.8 94.4*
Opium 34.9 34.5 4.5 5.6
Cannabis 48.8 49.0 13.6 29.8*
Alcohol 76.3 83.6* 43.6 72.0*
30-day prevalence
Heroin 68.8 70.2 15.3 83.8*
Opium 22.3 17.1 0.9 2.0
Cannabis 43.5 44.8 11.1 26.0*
Alcohol 71.4 77.9 39.6 69.1*
Health status and overdose experience
Physical health score, mean (SD)f 14.2 (9.1) 11.9* (8.5) 11.5 (9.5) 9.4* (7.7)
Mental health score, mean (SD)f 11.7 (8.0) 10.3* (8.1) 9.9 (8.8) 8.5* (8.0)
HIV diagnosed (ever) 19.0 12.7 12.5 9.8
HCV diagnosed (ever) 56.3 30.4* 23.1 19.3
TB diagnosed (ever) 23.5 13.4* 13.3 20.1*
Opioid-related overdose (ever) 57.7 38.6* 48.7 68.9*
PWUD people who use drugs
*Indicates a significant result (p = 0.05 or smaller) between group A and group B in each country
aStable accommodation includes living in own, parents’, or spouse’s apartment
bStable partnership is based on the judgment of the respondent
cDatabase: only person with children
dRegularly employed includes regular, full-time, or part-time work as well as students
eOnly people who consumed opioids in the last 30 days: KAZ: NGroupA = 207, NGroupB = 210; KRG: NGroupA = 69, NGroupB = 375
fBased on MAP: the sum score can range from 0 (very good) to 40 (very bad)
Rosenkranz et al. Harm Reduction Journal  (2016) 13:3 Page 6 of 11
In general, all groups of PWUD in this sample showed
high infection rates of diseases such as HIV (between 10
and 20 %), HCV (between 20 % and more than 50 %), and
tuberculosis (TB) (between 13 % and almost 25 %). Fur-
thermore, the prevalence of HIV as well as HCV infections
was higher in group A than in group B without reaching
significance in Kyrgyzstan. Regarding TB infections, the
prevalence was higher in group B from Kyrgyzstan.
More than half (57.5 %) of the registered PWUD in
Kazakhstan have ever experienced an opioid-related
overdose. In Kyrgyzstan, two thirds of the non-
registered PWUD have been affected by an overdose at
least once in their lifetime, with this being a 20 % greater
rate than among the registered PWUD.
Access to health care
According to the World Health Organization (WHO),
“preventing HIV transmission through injecting drug
use is one of the key challenges to universal access in
the health sector. A comprehensive package for the pre-
vention, treatment and care of HIV among IDUs in-
cludes […] nine interventions.” [20, 22, 29]. The PWUD
in our sample were asked about utilization of these nine
interventions (see Table 2).
Except for antiretroviral therapy (ART), which was uti-
lized only by very few PWUD (3–10 %), we could find
high rates of utilization for all listed interventions. With
the exception of vaccination/treatment of hepatitis in
the Kazakhstan sample (which was not statistically sig-
nificant), the registered PWUD showed higher rates of
utilization than the non-registered drug users.2 Further-
more, one quarter of group B in the Kyrgyzstan sample
as well as every tenth non-registered Kazakh PWUD de-
clared never having utilized any services.
One of the most important drug treatment interven-
tions regarding the improvement of health of injecting










N = 301 N = 299 N = 450 N = 450
Utilization of nine interventions (ever)a
HIV testing and counseling (T&C) 95.0 77.9* 97.1 62.4*
Prevention, diagnosis, and treatment of tuberculosis (TB) 93.0 81.9* 94.2 65.8*
Targeted information, education, and communication (IEC) for IDUs
and their sexual partners
89.0 60.5* 95.3 63.8*
Needle and syringe programs (NSPs) 71.4 45.2* 76.0 46.9*
Opioid substitution therapy (OST) and other drug dependence treatment 80.7 15.7* 95.8 27.1*
Condom programs for IDUs and their sexual partners 69.8 41.8* 81.6 47.6*
Vaccination, diagnosis, and treatment of viral hepatitis 54.4 55.5 83.8 56.4*
Prevention and treatment of sexually transmitted infections (STIs) 53.3 52.5 82.7 55.3*
Antiretroviral therapy (ART)b 6.6 2.7* 9.6 6.2
None of the above 0.3 10.7* 0.2 24.2*
Utilization of drug-related services (ever)a
Detoxification without methadone 46.3 9.2* 23.6 13.2*
Opioid substitution therapy 28.0 1.7* 90.4 0.4*
Psychotherapy 20.7 7.8* 11.3 8.1
Brief intervention/motivational interviewing/consulting 19.3 2.0* 11.6 8.7
Social rehabilitation programs 13.0 2.0* 3.8 4.5
Maintenance therapy with naltrexone or other opioid antagonist 11.3 5.1* 1.6 1.6
Detoxification with methadone 9.7 1.0* 20.4 4.3*
Relapse prevention training 7.0 1.0* 4.4 4.5
Self-help groups (12-step program) 5.3 1.4* 8.0 10.1
None of the above 19.0 84.0* 4.2 72.5*
IDUs injecting drug users, PWUD people who use drugs
*Indicates a significant result (p = 0.05 or smaller) between group A and group B in each country
aMultiple response
bDatabase: only HIV-infected PWUD
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drug users is OST. With respect to specific interventions
and drug treatments, the group differences became more
apparent (see Table 2).
Detoxification without methadone and OST were the
two main interventions as they showed the highest rates of
utilization. OST was utilized by around one quarter of reg-
istered PWUD from Kazakhstan, whereas in Kyrgyzstan,
more than 90 % reported having utilized OST. It is par-
ticularly worth mentioning that OST was hardly ever uti-
lized by non-registered PWUD.
Furthermore, a large percentage (73–84 %) of the non-
registered PWUD did not utilize any of the listed drug-
related services at all. On the other hand, this applied
also to almost a fifth of the registered PWUD from
Kazakhstan.
In order to enhance the access of PWUD to the ser-
vice providers, it is important to know why so many
PWUD are not utilizing drug-related services. The bar-
riers to utilization are shown in Table 3.
The main reason was the belief that they do not require
treatment. This was affirmed by the largest percentage of
PWUD from both groups in both countries. Besides the
fact that only very few registered PWUD (KAZ, N = 55;
KRG, N = 8) answered this question at all, the results of
the non-registered PWUD were of special interest: Inter-
viewees from both countries indicated fear of registration
with narcology, worries about problems with the police,
and fear of becoming stigmatized by other people as im-
portant barriers to utilization. But also general mistrust of
governmental facilities and skepticism of the effectiveness
of the available treatment may have played a role in the
decision of non-registered PWUD not to utilize drug-
related treatment.
Discussion
Illicit drug use, living conditions, and health status of
PWUD, as well as their access and actual utilization of
health care- and drug-related services were investigated
for two groups that differ regarding their affinity to
treatment providers and the official health care system.
We assumed to find differences especially regarding ac-
cess and utilization of services between PWUD being
registered with a NC and non-registered PWUD.
The proportion of male persons among interviewed
PWUD amounted to three quarters. The predominantly
male gender of PWUD corresponded to international
and regional findings [10, 30, 31]. In Kyrgyzstan’s group
A, the proportion of males was noticeably higher. This
could be explained by the greater proportion of men in
OST which is the most frequently utilized drug-related
service in this country.
Although the findings included well-known social prob-
lems such as homelessness or unemployment, it is of par-
ticular importance for the adjustment of the treatment
system to tie in with positive findings such as stable accom-
modation (75 to 90 %), stable partnerships (53 to 65 %),
and responsibility for minor children (60 to 80 %). This also
means that drawing on existing familial resources is of
great importance for social and health-related care.
In contrast to international research where high rates
of unemployment of PWUD are often described, e.g.,
[10, 32], our study revealed a different picture: In
Kazakhstan, where PWUD are generally younger, their
employment situation was even more advantageous
(more than 50 % in regular employment) than among
Kyrgyzstan’s rather older PWUD (around one third in
regular employment).










N = 55 N = 283 N = 8 N = 307
Barriers to utilization of drug-related servicesa
I think I do not need treatment 76.4 60.9* 75.0 62.9
I think that current available treatment is not effective 29.1 29.0 25.0 16.3
I heard stories about the treatment regime that made me dislike it 25.5 19.3 62.5 9.8*
I heard stories about treatment staff that made me dislike it 16.4 15.1 50.0 5.2*
I cannot afford to pay for treatment/treatment is too expensive 14.5 15.5 50.0 17.3*
I do not trust governmental facilities 12.7 21.8 37.5 10.7*
I am afraid of problems with police if they know I was in treatment
as a drug user
10.9 41.2* 37.5 19.9
Afraid that then everybody will know I am a drug user 9.1 41.2* 25.0 36.2
I do not want to be registered with narcology 7.3 51.3* 12.5 24.4
PWUD people who use drugs
*Indicates a significant result (p = 0.05 or smaller) between group A and group B in each country
aMultiple response, only people who never received drug-related treatment
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The results regarding drug use showed that both
groups consisted of mainly long-term opioid-dependent
persons who usually consumed intravenously. Further,
we surveyed polyvalent consumption patterns with high
proportions of (additional) cannabis and alcohol use.
Observing current consumption patterns, indications
for an impact of the treatment system on these patterns
were only found in group A from Kyrgyzstan. This can
be explained by the broad implementation of OST in
Kyrgyzstan. In this group, the consumption of heroin
and all other substances was noticeably and significantly
lower than in the group of non-registered PWUD.
In general, the health situation of PWUD was rela-
tively poor, particularly regarding registered PWUD.
One explanation for the worse health condition of regis-
tered PWUD might be their higher mean age.
HIV and HCV prevalence was higher in the whole sam-
ple if compared with existing epidemiological data from
Kazakhstan and Kyrgyzstan [10, 13, 16]. In group A, this
could be related to the fact that registered PWUD did have
a poorer health in general. In group B, the high prevalence
might be associated with the sampling procedure: The
non-registered PWUD were often recruited in the periph-
ery of institutions which cooperate with AIDS centers.
Therefore, HIV- and/or HCV-infected PWUD who uti-
lized services of these centers or trust points might have
had a higher probability of being recruited for the study.
Regarding the results of the utilization of the “nine in-
terventions” recommended by WHO [29], it was demon-
strated that in both countries all interventions which
showed significant group differences were more fre-
quently utilized by PWUD from group A than from
group B. This is particularly obvious regarding the inter-
vention “OST and other drug dependence treatment.” In
addition, we found high utilization rates of non-
registered PWUD regarding general harm reduction
measures, which indicates a high range of coverage of
these measures. Though based on only a very small
number of cases, the low utilization of ART (3 to 10 %)
in the sample, however, suggests a need for action in im-
proving the implementation of this important measure
for HIV-infected PWUD.
Taking these results into account, group B seems to be
an adequate sample to describe PWUD who are in con-
tact with the low-threshold section of the health care
system for PWUD, which is often provided in and
around AIDS centers. The high rates of utilization sug-
gest that the implementation of harm reduction mea-
sures for PWUD who are not integrated in the
governmental health care system is successful. The re-
spective situation in Kyrgyzstan seems to be even better
than in Kazakhstan.
Regarding the utilization of OST and other drug de-
pendence treatment, the difference between registered
and non-registered PWUD is very clear; 84 % resp. 73 %
of the non-registered PWUD in Kazakhstan and
Kyrgyzstan declared no utilization at all, whereas these
proportions were much lower in both groups of regis-
tered PWUD. In both countries, the most frequently uti-
lized intervention in group B was detoxification without
methadone. In Kazakhstan, OST—the most important
intervention for opioid drug users—was utilized only by
very few non-registered PWUD. Around 30 % of the reg-
istered Kazakh PWUD in our sample were treated with
OST. As only very few PWUD in the whole country
took part in OST programs [10], it is possible that our
sample contains a bias in terms of an overrepresentation
of OST clients.
Looking at the results from Kyrgyzstan, almost none
of the non-registered PWUD reported ever having uti-
lized OST which is an evidence-based and important
treatment measure normally provided by NCs. This
leads to the question which barriers prevent non-
registered PWUD from utilizing treatment services. The
most important barrier in all four groups was the as-
sumption not to need treatment. This might indicate a
lack of information about the severity of drug depend-
ence as disease and the necessity of treatment. It is fur-
ther conceivable that particularly those PWUD not (yet)
living in social disintegration perceived no special need
for treatment.
A further look at the barriers reported by non-
registered PWUD in both countries reveals three main
reasons. Firstly, these persons were either afraid of being
registered or they mistrusted governmental facilities in
general. Secondly, many non-registered PWUD thought
that the provided treatment was not effective. Thirdly,
they were afraid of being stigmatized or of getting in
trouble if the police or neighbors and acquaintances
found out that they were drug users. This concern
(maybe based on bad experiences made by PWUD in
the past) raises doubt regarding the extent of confidenti-
ality on the side of the health care staff. The information
deficit regarding the effectiveness of treatment as well as
the mistrust of governmental facilities could be changed
in a medium-term perspective; the reduction of
stigmatization is a long-term task of society.
Limitations
Besides the general problem of social desirability of an-
swers to delicate questions (which are a particular issue
for the PWUD in our study as they are often skeptical
towards the public treatment system), the main limita-
tion of the study is that the utilization of health services
(“nine interventions”) is probably overestimated. This is
related to the practical implementation of the sampling
strategy in the selected regions. A bias may have oc-
curred due to the access to group B: the recruiters were
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registered PWUD; therefore, the recruited members of
the non-registered opioid users’ population have one
thing in common: all of them know at least one person
who is in the Narcological Register.
In addition, regarding recruitment problems, the ac-
cess to both groups was realized in AIDS centers, trust
points, and other locations where outpatient treatment
is offered. These PWUD probably have a higher affinity
to the health care system than other PWUD who could
not be reached and could not be included in the sample.
Therefore, the sampling strategy may have facilitated
only a limited access to the so-called “hidden popula-
tion” of PWUD.
Conclusions
The general access to the health care system, especially
for non-registered PWUD, has been opened through
low-threshold facilities. However, utilization rates of
non-registered PWUD show that the access to specific
drug treatment is too limited and ought to be broad-
ened. Besides that, the provision of OST should be ex-
panded especially in Kazakhstan where the number of
registered PWUD utilizing OST is rather low.
Furthermore, the access to OST should also be avail-
able for non-registered PWUD. This could be realized
by involving existing trust points, as the fear of being
registered with narcology (as a consequence of entering
official drug treatment) was indicated by PWUD as one
of the most important barriers regarding the utilization
of official drug-related services. Trust points could fur-
ther help overcome another important barrier of
utilization: Many PWUD are convinced neither of their
need for treatment nor of the effectiveness of drug treat-
ment in general. By providing specific and target group-
related information about modern drug treatment, these
institutions can contribute to enhance the number of
PWUD who utilize existing drug-related services. This
could help individuals as well as the countries as a whole
to deal with health and societal problems connected
with drug use in a more effective way.
Endnotes
1In this document, the abbreviation PWUD is used to
refer to opioid drug use. This is due to the fact that
there is no official WHO abbreviation for this group of
drug users. We did not choose the term “injecting drug
user” (IDU) as most, but not all, PWUD in our sample
are injecting drug users.
2The health services for non-registered PWUD are
provided mainly by AIDS centers (except for OST).
Utilization of services in AIDS centers does not lead to a
registration with the Narcological Register.
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